Condition
Breast Cancer With Brain Metastasis
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Not Yet Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07152782Phase 2Not Yet RecruitingPrimary
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07150208Phase 2Not Yet RecruitingPrimary
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
NCT01924351Phase 2WithdrawnPrimary
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
Showing all 3 trials